

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities.

The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) and Hong Kong Securities Clearing Company Limited (“HKSCC”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



上海復旦張江生物醫藥股份有限公司
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. *

(a joint stock company incorporated in the People’s Republic of China with limited liability)

**LISTING ON
THE GROWTH ENTERPRISE MARKET OF
THE STOCK EXCHANGE OF HONG KONG LIMITED
BY WAY OF PLACING OF H SHARES**

Number of Placing Shares: 198,000,000 H Shares, including 18,000,000 H Shares to be converted from Domestic Shares
Offer Price : not more than HK\$1.40 per H Share and expected to be not less than HK\$1.13 per H Share
Nominal value : RMB0.10 per H Share
Stock Code : 8231

Sponsor



Guotai Junan Capital Limited

Financial Adviser



Barits Securities (Hong Kong) Limited

Joint Lead Managers



Barits Securities (Hong Kong) Limited



Guotai Junan Securities (Hong Kong) Limited

Co-Lead Manager

Nomura International (Hong Kong) Limited

Co-Managers

CAF Securities Company Limited
First Shanghai Securities Limited
Hantec Capital Limited
Phoenix Capital Securities Limited
Shun Loong Securities Company Limited
Toyo Securities Asia Limited

Core Pacific-Yamaichi International (H.K.) Limited
Grand Cathay Securities (Hong Kong) Limited
Kingsway SW Securities Limited
Shenyin Wanguo Capital (H.K.) Limited
Tai Fook Securities Company Limited
Wintech Securities Ltd

Terms used in this announcement, unless defined herein, shall have the same meanings as those defined in the prospectus dated 31st July, 2002 (the “Prospectus”) issued by 上海復旦張江生物醫藥股份有限公司 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (the “Company”).

Application has been made to the Stock Exchange for the listing of and permission to deal in the H shares (“H Shares”) of RMB0.10 each in the share capital of the Company, to be issued as described in the Prospectus. Dealings in the H Shares on the Growth Enterprise Market of the Stock Exchange (“GEM”) are expected to commence on Tuesday, 13th August, 2002.

Copies of the Prospectus required by the Rules Governing the Listing of Securities on GEM are available, for information purposes only, during normal office hours (9:00 a.m. – 5:00 p.m.) from Barits Securities (Hong Kong) Limited at Rooms 3403-3407, 34/F., Edinburgh Tower, The Landmark, 15 Queen’s Central Road, Hong Kong, and Guotai Junan Securities (Hong Kong) Limited at 27th Floor, Low Block, Grand Millennium Plaza, 181 Queen’s Road Central, Hong Kong for a period of 14 days from 31st July, 2002 to 13th August, 2002 (both dates inclusive).

Application for the H Shares will only be considered on the basis of the terms and conditions of the Prospectus.

Subject to granting of listing of, and permission to deal in, the H Shares on GEM and the compliance with the stock admission requirements of HKSCC, the H Shares will be accepted as eligible securities by HKSCC for deposit, clearance and settlement in Central Clearing And Settlement System (“CCASS”) with effect from the date of commencement of dealings in the H Shares on GEM or on any other date HKSCC chooses. All activities under CCASS are subject to the General Rules of CCASS and CCASS Operational Procedures in effect from time to time.

By order of the board
上海復旦張江生物醫藥股份有限公司
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.*
Wang Hai Bo
Managing Director

Hong Kong, 31st July, 2002

This announcement and a copy of the Prospectus will appear on the GEM website (www.hkgem.com).

** For identification purpose only*